Simulations Plus, Inc. (NASDAQ:SLP) Q4 2024 Earnings Conference Call October 23, 2024 5:00 PM ET
Company Participants
Lisa Fortuna - Investor Relations, Financial Profiles
Shawn O'Connor - Chief Executive Officer
William Frederick - Chief Financial Officer & Chief Operating Officer
Conference Call Participants
Max Smock - William Blair & Co. LLC.
Matthew Hewitt - Craig-Hallum Capital Group
David Larsen - BTIG
Scott Schoenhaus - KeyBanc Capital Markets Inc.
Francois Brisebois - Oppenheimer & Company
Constantine Davides - Citizens JMP
Operator
Greetings, and welcome to the Simulations Plus Fourth Quarter and Fiscal Year 2024 Financial Results Conference Call. [Operator Instructions ] As a reminder, this conference call is being recorded.
It is now my pleasure to introduce Lisa Fortuna from Financial Profiles. Ms. Fortuna, you may now begin.
Lisa Fortuna
Good afternoon, everyone. Welcome to the Simulations Plus Fourth Quarter and Fiscal 2024 Financial Results Conference Call. With me today are Shawn O'Connor, Chief Executive Officer; and Will Frederick, Chief Financial Officer and Chief Operating Officer of Simulations Plus.
Please note that we updated our quarterly earnings presentation, which will serve as a supplement to today's prepared remarks. You can access the presentation on our Investor Relations website at www.simulations-plus.com. After management's commentary, we will open the call for questions. As a reminder, the information discussed today may include forward-looking statements that involve risks and uncertainties. Words like believe, expect and anticipate refer to our best estimates as of this call, and actual future results could differ significantly from these statements. Further information on the company's risk factors is contained in the company's quarterly and annual reports and filed with the Securities and Exchange Commission.
With that, I'll turn the call over to Shawn. Please go ahead.
Shawn O'Connor
Thank you, Lisa. Good afternoon, everyone, and thank you for joining our fourth quarter and fiscal 2024 conference call. Our team delivered strong results in 2024. Total revenue increased 18% year-over-year and 14% on an organic basis, excluding the fourth quarter contribution from Pro-ficiency. The organic growth rate was above the 10.5% growth rate we achieved in fiscal 2023, and at the high end of our guidance provided at the beginning of the fiscal year. Full year diluted EPS of $0.49 exceeded the high end of our guidance range of $0.46 to $0.48.
Turning to key highlights of the year, as an industry leader in biosimulation software tools, we continue to improve our competitive edge during fiscal 2024, with major upgrades across our platform supporting PBPK, PK/PD and drug discovery. Our release of GPX in May, significantly enhanced our flagship GastroPlus, PBPK platform with advanced models, refined algorithms and integrated machine learning technology. GastroPlus greatly enriches the user experience with an intuitive interface, streamlined workflows and faster processing.